This is because, when administered as a rapid infusion, the peak tissue concentration of carboplatin is high, and a high level of DNA damage is induced in cancer cells from which they are unlikely to recover, irrespective of changes in intracellular Bcl-xL levels. The gene discussed is BCL2L1; the disease is cancer.